Taxus Cardium Pharmaceuticals Group Inc (CRXM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Summary
Taxus Cardium Pharmaceuticals Group Inc (Cardium) is a development stage company with focus on regenerative medicine. It develops manufacturing process and technology platforms for cardiovascular disease, wound healing and tissue engineering based on its core gene therapy. Its product portfolio includes FDA approved Excellagen topical gel, a cellular biological skin substitute used for wound care management; and Generx, an interventional cardiology, angiogenic gene therapy product candidate used for the treatment of cardiac microvascular insufficiency. The company also holds non-core interests in the Cell-nique d/b/a Healthy Brands Collective, a health products company, and LifeAgain Insurance Solutions, Inc., an advanced medical data analytics business. Cardium markets its products through third party commercialization partners. The company is headquartered in San Diego, California, the US.
Taxus Cardium Pharmaceuticals Group Inc (CRXM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Taxus Cardium Pharmaceuticals Group Inc (Cardium) is a development stage company with focus on regenerative medicine. It develops manufacturing process and technology platforms for cardiovascular disease, wound healing and tissue engineering based on its core gene therapy. Its product portfolio includes FDA approved Excellagen topical gel, a cellular biological skin substitute used for wound care management; and Generx, an interventional cardiology, angiogenic gene therapy product candidate used for the treatment of cardiac microvascular insufficiency. The company also holds non-core interests in the Cell-nique d/b/a Healthy Brands Collective, a health products company, and LifeAgain Insurance Solutions, Inc., an advanced medical data analytics business. Cardium markets its products through third party commercialization partners. The company is headquartered in San Diego, California, the US.
Taxus Cardium Pharmaceuticals Group Inc (CRXM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.
Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.
Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.
Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
TABLE OF CONTENTS
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Gemphire Therapeutics Raises USD5 Million in Financing Round 10
Gemphire Therapeutics Raises USD5 Million in Series A Financing Round 11
Merger 12
Michigan Life Therapeutics Merges with Gemphire Therapeutics 12
Licensing Agreements 13
Gemphire Therapeutics Enters into Licensing Agreement with Pfizer 13
Equity Offering 14
Gemphire Therapeutics Plans to Raise up to USD26 Million in Public Offering of Shares 14
Gemphire Therapeutics Raises USD12.5 Million in Private Placement of Units 15
Gemphire Therapeutics Raises USD30 Million in IPO 16
Gemphire Therapeutics Raises USD1.5 Million in Private Placement of Shares 18
Debt Offering 19
Gemphire Therapeutics Raises USD5 Million in Private Placement of Notes 19
Gemphire Therapeutics Raises USD0.2 Million in Private Placement of Notes 20
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 21
Gemphire Therapeutics Raises USD2.8 Million in Private Placement of Notes 22
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 23
Gemphire Therapeutics Inc - Key Competitors 24
Gemphire Therapeutics Inc - Key Employees 25
Gemphire Therapeutics Inc - Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 14, 2017: Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update 27
May 09, 2017: Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update 29
Mar 15, 2017: Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update 31
Nov 02, 2016: Gemphire Announces Third Quarter 2016 Financial Results and Provides Corporate Update 34
Corporate Communications 36
May 30, 2017: Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch 36
Mar 29, 2017: Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 37
Oct 06, 2016: Gemphire Therapeutics Appoints Lee Golden, M.D., as Chief Medical Officer 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List Of Tables
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gemphire Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Gemphire Therapeutics Raises USD5 Million in Financing Round 10
Gemphire Therapeutics Raises USD5 Million in Series A Financing Round 11
Michigan Life Therapeutics Merges with Gemphire Therapeutics 12
Gemphire Therapeutics Enters into Licensing Agreement with Pfizer 13
Gemphire Therapeutics Plans to Raise up to USD26 Million in Public Offering of Shares 14
Gemphire Therapeutics Raises USD12.5 Million in Private Placement of Units 15
Gemphire Therapeutics Raises USD30 Million in IPO 16
Gemphire Therapeutics Raises USD1.5 Million in Private Placement of Shares 18
Gemphire Therapeutics Raises USD5 Million in Private Placement of Notes 19
Gemphire Therapeutics Raises USD0.2 Million in Private Placement of Notes 20
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 21
Gemphire Therapeutics Raises USD2.8 Million in Private Placement of Notes 22
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 23
Gemphire Therapeutics Inc, Key Competitors 24
Gemphire Therapeutics Inc, Key Employees 25
List Of Figures
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
RELATED REPORTS
Taxus Cardium Pharmaceuticals Group Inc (CRXM) - Medical Equipment - Deals and Alliances Profile
Taxus Cardium Pharmaceuticals Group Inc (Cardium) is a development stage company with focus on regenerative medicine. It develops manufacturing process and technology platforms for cardiovascular disease, wound healing and tissue
View ReportTaxus Cardium Pharmaceuticals Group Inc (CRXM) - Financial and Strategic SWOT Analysis Review
Taxus Cardium Pharmaceuticals Group Inc (CRXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the companys businesses and operations. The profile has been
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
